STAT News: FDA Peptide Compounding Shift and Iran Conflict Impact on Clinical Trials
STAT's pharmaceutical roundup covers the FDA's expected move to allow compounding of previously banned peptides and the impact of the Iran conflict on global clinical trial recruitment.